(Q37765187)

22 August 2017

1 reference

title

Clinical developments in nanotechnology for cancer therapy (English)

1 reference

22 August 2017

0 references

Jeremy D Heidel

1

1 reference

22 August 2017

Mark E Davis

series ordinal

2

1 reference

22 August 2017

publication date

12 June 2010

1 reference

22 August 2017

published in

Pharmaceutical Research

1 reference

22 August 2017

volume

28

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

187-199

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Nanotechnology and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Renal clearance of quantum dots

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Mediating tumor targeting efficiency of nanoparticles through design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Liposome-based drug delivery in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

siRNA conjugate delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Pharmacokinetics and biodistribution of nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Polymeric tubulysin-peptide nanoparticles with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Selective tumor cell targeting using low-affinity, multivalent interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Functionalized micellar systems for cancer targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Relationships between the structure of taxol analogs and their antimitotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Polymer-drug conjugates: recent development in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Development and characterization of a novel liposome-based formulation of SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Synthesis of a macromolecular camptothecin conjugate with dual phase drug release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Evolving role of pegylated interferons in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Review on Medusa:a polymer-based sustained release technology for protein and peptide drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0178-7

PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2

21 January 2018

1 reference

12 December 2020

Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes

1 reference

12 December 2020

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

1 reference

12 December 2020

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

1 reference

12 December 2020

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

1 reference

12 December 2020

On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level

1 reference

12 December 2020

Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes

1 reference

12 December 2020

In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation

1 reference

12 December 2020

Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles

1 reference

12 December 2020

Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes

1 reference

12 December 2020

Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes

1 reference

12 December 2020

Pegasparaginase: where do we stand?

1 reference

12 December 2020

Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer

1 reference

12 December 2020

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

12 December 2020

Delivery of therapeutic proteins

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy

1 reference

12 December 2020

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

1 reference

12 December 2020

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial

1 reference

12 December 2020

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors

1 reference

12 December 2020

Clinical pharmacology of polyethylene glycol-L-asparaginase

1 reference

12 December 2020

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1 reference

12 December 2020

Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection

1 reference

12 December 2020

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study

1 reference

12 December 2020

Cardiac safety of liposomal anthracyclines

1 reference

12 December 2020

Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors

1 reference

12 December 2020

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

1 reference

12 December 2020

Pegaptanib sodium for the treatment of age-related macular degeneration

1 reference

12 December 2020

10.1007/S11095-010-0178-7

Identifiers

DOI

1 reference

22 August 2017

1 reference